A Comparative Study of Serum Prostate Specific Antigen Levels in Patients Suffering from Prostatic & Non-prostatic Cancers

authors:

avatar H Kharrazi 1 , * , avatar N Amiri Fard 1 , avatar M Rezaei 1

Iran
Journal of Kermanshah University of Medical Sciences: Vol.8, issue 2; e81329
published online: June 19, 2004
article type: Research Article
received: May 05, 2004
accepted: August 10, 2004

how to cite: Kharrazi H, Amiri Fard N, Rezaei M. A Comparative Study of Serum Prostate Specific Antigen Levels in Patients Suffering from Prostatic & Non-prostatic Cancers. J Kermanshah Univ Med Sci. 2004;8(2):e81329. 

Abstract

Introduction: Prostatic specific antigen (PSA) is an important tumor marker of prostatic cancer and antigenic determinant of prostatic tissue. However, recently, results of several  researches have proposed existence of PSA in non- prostatic tumors, extracts . In this study, our goal was to find that if patients with non-prostatic cancers synthesize PSA.
Materials & Methods: The sample was selected from patients reffered to Imam Khomeini Hospital of Tehran, Institute Center for Cancer Research and Talaghani Hospital of Kermanshah during 2000-2001 , and some healthy subjects. They were 167, including 29 healthy subjects and 138 patients (62 female and 76 male), who suffered from 23 sorts of non–prostate cancers and prostate cancer. To measure PSA, the Immuno Radiometric Assay (IRMA) method was employed. The obtained data were analyzed by descriptive and inferential statistics (Mann–Wittny and indepcndant T– test were employed).
Results: It was showed that the mean of Serum PSA (SPSA) was 66.31±29.21(ng/ml) in men with prostate cancer, 11.84±11.7 in men with colon cancer, 0.96±0.65 in men with other non-prostatic cancers and 1.38±0.96 in healthy men. In women with breast cancer it was 0.2±0.11, in women with the other cancers, 0.2±0.11 and in healthy women 0.045±0.035.
Comparing the mean of SPSA in men with prostate cancer and those with non-prostate cancers, It was indicated that the difference between the means was statistically significant (P<0.001). By the way, the results also showed that the difference between the mean of PSA in colon cancer with that of non-prostate cancers was
statistically significant (P<0.04). Finally it was indicated that the difference between the mean of SPSA in healthy scancerous women  was statistically significant too.
Conclusion: These data not only confirm the particular role of SPSA assay in diagnosis and follow up of prostate cancer as a specific tumor marker, but also, suggest usefulness of SPSA assay in prediciting prognosis and diagnosis of some non-prostatic cancers.

Fulltext

The full text of this article is available on PDF